Alveolus Bio, Inc.
Publicly observedBirmingham, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Birmingham | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Alveolus Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | CZDCV9W7CRC4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant11 Sept 2026Publicly observed
NIH SBIR/STTR award: An Inhaled Live Biotherapeutic for Influenza Viral Infection
USD 273,123.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Leveraging Live Biotherapeutics for the Treatment of Chronic Rhinosinusitis
USD 301,768.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Mar 2023Publicly observed
NIH SBIR/STTR award: An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
USD 992,385.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.